The Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority has issued a Broad Agency Announcement (BAA) to develop new chemical, biological, radiological and nuclear therapeutics, including the development of new indications for already licensed therapeutics, as novel medical countermeasures for the treatment of populations exposed to acute radiation. Titled Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation, contracts will be awarded to fund development of therapies to replenish hematopoietic lineages, recover bone marrow stromal loss and treat vascular injuries. Sol. No. BAA-BARDA-08-08. Respond by April 17. Contact: Carl Newman, contract specialist, 202-205-1156, [email protected].
free preview